

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines
GLOBAL PHARMATECH INC.
Flat/RM 705, 7/F, Fa Yuen Commercial Building
No. 75, Fa Yuen Street, Mong Kok, KL, Hong Kong

Quarterly Report

For the period ending June 30, 2024 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

395,211,785 as of June 30, 2024

395,211,785 as of December 31, 2023

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Formerly=Autocarbon.com Inc. until 2-05

Current State and Date of Incorporation or Registration: Delaware – June 26, 2001

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

Flat/RM 705, 7/F, Fa Yuen Commercial Building
No. 75, Fa Yuen Street, Mong Kok, KL, Hong Kong

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Pacific Stock Transfer Company

Phone: 702-361-3033

Email: Luke <Luke@pacificstocktransfer.com>

Address: 6725 Via Austi Pkwy., Ste. 300
Las Vegas, NV 89119

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>GBLP</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>37945N109</u>	
Par or stated value:	<u>.0001</u>	
Total shares authorized:	<u>700,000,000</u>	<u>as of date: June 30, 2024</u>
Total shares outstanding:	<u>395,211,785</u>	<u>as of date: June 30, 2024</u>
Total number of shareholders of record:	<u>140</u>	<u>as of date: June 30, 2024</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Trading symbol:	<u> </u>	
Exact title and class of securities outstanding:	<u>Preferred A</u>	
CUSIP:	<u> </u>	
Par or stated value:	<u>.0001</u>	
Total shares authorized:	<u>10,000,000</u>	<u>as of date: June 30,, 2024</u>
Total shares outstanding:	<u>9,750,000</u>	<u>as of date: June 30,, 2024</u>
Total number of shareholders of record:	<u>1</u>	<u>as of date: June 30,, 2024</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. **For common equity, describe any dividend, voting and preemption rights.**

No dividend, each common share has one vote, no preemption rights

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

No Dividend. The Convertible Preferred Stock - One Preferred Share for One Thousand Voting Right; One Preferred Share can be converted into One Thousand Common Shares

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
Opening Balance									
Date <u>12.31.21</u> Common: <u>276,351,785</u> Preferred: <u>9,750,000</u>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>05.26.2021</u>	<u>New</u>	<u>10,000,000</u>	<u>Preferred</u>	<u>0.0001</u>	<u>No</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	
<u>12/03/2021</u> * -	<u>New / Preferred to Common conversion</u>	<u>250,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>No</u>	<u>Yong Sheng</u>	<u>Preferred Share conversion</u>	<u>Restricted</u>	
<u>12/27/2021</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.0235</u>	<u>Yes</u>	<u>Juan Peng</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>

<u>12/27/2021</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.0235</u>	<u>Yes</u>	<u>Haibo Li</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/27/2021</u>	<u>New</u>	<u>300,000</u>	<u>Common</u>	<u>0.0235</u>	<u>Yes</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>08/29/2022</u>	<u>New</u>	<u>1,200,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Haibo Li</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>08/29/2022</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Dong Ming Zhao</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>08/29/2022</u>	<u>New</u>	<u>500,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>1,500,00</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Haibo Li</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Dong Ming Zhao</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Yinchen Liu</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>300,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>85,200,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Meisheng Liao</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>15,160,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Ruiqi Sheng</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>5,400,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Guanghua Wen</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>4,600,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Chi Zhang</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>2,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Jianhua Zhu</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
Shares Outstanding on Date of This Report:									
	<u>Ending</u>	<u>Balance</u>							
<u>Ending Balance:</u>									
Date <u>06.30.24</u> Common: <u>395,211,785</u>									
Preferred: <u>9,750,000</u>									

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

Use the space below to provide any additional details, including footnotes to the table above:

- Yong Sheng converted 250,000 Preferred Shares to 250,000,000 common shares

<u>8.30.21</u>	<u>Transfer</u>	<u>10,000,000</u>	<u>Preferred</u>	<u>.0001</u>	<u>No</u>	<u>Yong Sheng</u>	<u>Transfer from Caren Currier</u>	<u>Restricted</u>
<u>12/03/2021</u>	<u>Transfer</u>	<u>9,750,000</u>	<u>Preferred</u>	<u>0.0001</u>	<u>No</u>	<u>Kingwood International Holding LTD Yong Sheng</u>	<u>Transfer</u>	<u>Restricted</u>

- According to the Share Exchange Agreement, GBLP has issued 112,360,000 common shares in aggregate to the shareholders of Botaniex, Inc.
- Details of the newly issued 112,360,000 common shares are listed in the Report.

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

<u>Date of Note Issuance</u>	<u>Outstanding Balance (\$)</u>	<u>Principal Amount at Issuance (\$)</u>	<u>Interest Accrued (\$)</u>	<u>Maturity Date</u>	<u>Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)</u>	<u>Name of Noteholder.</u> <small>*You must disclose the control person(s) for any entities listed.</small>	<u>Reason for Issuance (e.g. Loan, Services, etc.)</u>
<u>7.1.21</u>	<u>40,000</u>	<u>40,000</u>	<u>0</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001. Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;</u>	<u>Haizhen Liao</u> <u>The convertible note was assigned to Haizhen Liao from Kingstone Financial Inc on October 18, 2022</u>	<u>Loan</u>
<u>8.1.21</u>	<u>10,000</u>	<u>10,000</u>	<u>0</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001. Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;</u>	<u>Xiyu Zhang</u> <u>The convertible note was assigned to Haizhen Liao from Kingstone Financial Inc on October 18, 2022</u>	<u>Loan</u>
<u>3.24.22</u>	<u>10,000</u>	<u>10,000</u>	<u>0</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001. Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;</u>	<u>Juan Peng</u>	<u>Loan</u>
<u>11/15/22</u>	<u>10,000</u>	<u>10,000</u>	<u>0</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001. Whereas the Company and Note</u>	<u>Juan Peng</u>	<u>Loan</u>

					<u>Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;</u>		
<u>21/07/23</u>	<u>10,000</u>	<u>10,000</u>	<u>0</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001 Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;</u>	<u>Haizhen Liao</u>	<u>Loan</u>

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. (Please ensure that these descriptions are updated on the Company's Profile on www.otcm Markets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Global Pharmatech, Inc.(GBLP) incorporated a wholly owned subsidiary - Vitalia Health Inc. based in Toronto, Canada on April 29, 2023, and the subsidiary will focus on manufacturing and maketing of dietary supplements focus on anti-aging, anti-diebitics, immune enhancement, energy booster, and weight management as well as distribution of botanical extracts/herbal extracts in Canada.

Global Pharmatech, Inc.(GBLP) acquired 100% ownership of Botaniex, Inc. through the share exchange agreement executed on December 18, 2022, Botaniex, Inc. is a Delaware Corporation incorporated in 2005, and it has been operating through its 100% owned subsidiary of Changsha Botaniex, Inc. in China since 2005.

Botaniex is a market-oriented supplier & manufacturer of natural ingredients (botanical extracts/herbal extracts and herbal formulations) for the Industries of Dietary Supplements, Functional Foods, Functional Beverages, Cosmetics and Pharmaceuticals. By co-operating with the strategic partners like universities, Botaniex's R&D team is dedicated to development of the new natural ingredients and the herbal formulations focusing on men's health and women's health. In addition, both the advanced equipment and sophisticated technology are employed to produce the high quality and customized botanical extracts and herbal formula. We also provide customers with value added services such as Private Labels, Contract Manufacturing, and etc.

Currently Botaniex, Inc. owns the patents as follows:

- A Technology to Extract Sea Buckthorn Oil by Enzyme and CO2 (Super-Critical Fluid Extraction (Patent Number: ZL 2014-1-0009702.6);
- A Technology to Extract L-Theanine from Green Tea (Patent Number: ZL 2015-1-0578407.7);
- A Technology to Extract Actinidin from Kiwi Fruit (Patent Number: ZL 2013-1-0731769.6);

Furthermore, Botanies owns the following Trade Marks

- EJACON – a brand used for men's health products (Trade Mark#: 4998788)
- Slimmer-Trimmer – a brand used for weight management; (Trade Mark#: 4998779)

- Twin-Peaks – a brand used for women’s beauty (Trade Mark#: 5469534)

B. List any subsidiaries, parent company, or affiliated companies.

Vitalia Health Inc. based in Toronto, Canada, a wholly owned subsidiary of Global Pharmatech, Inc. Changsha Botaniex, Inc. is a subsidiary of 100% owned by Botaniex, Inc. Botaniex, Inc. registered a 100% owned subsidiary in Florida, but has no operations yet Global Pharmatech, Inc.(GBLP) is the parent company of all the above-mentioned companies/subsidiaries

C. Describe the issuers’ principal products or services.

Botaniex, In., as a wholly owned subsidiary of Global Pharmatech, Inc. provides the three categories of products and services:

- Herbal Extracts including Tea Extracts, Mushroom Extracts, Ginseng Extracts, Kiwi Fruit Extracts, Ginger Extracts, and etc;
- Herbal Formulation – Weight Loss, Male Enhancement, Immunity Enhancement, and etc’
- Value Added Services – Private Label/OEM

For more information about the products, please visit the company website: www.botaniex.com

5) Issuer’s Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Changsha Botaniex, Inc. has owned a 4,000 square feet office, located at 1-403, Building A4, Lu-Valley Compark, 27 Wenxuan Road, Lu-Valley High-Tech Development District, Changsha, China 410205

Vitalia Health Inc. has leased an office located in 205 Placer Ct. Unit 201, Toronto, Canada M2H 0A9

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer’s securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Yong Sheng</u>	<u>5%</u> <u>Director</u>	<u>Chenzhou, Hunan Province, China</u>	<u>250,000,000</u>	<u>Common</u>	<u>63.25%</u>	_____
<u>Kingwood International Holding Limited</u>	<u>5%</u>	<u>Hong Kong, China</u>	<u>9,750,000</u>	<u>Preferred</u>	<u>100%</u>	<u>Yong Sheng</u>
<u>Meisheng Liao**</u>	<u>5%</u> <u>CEO & President</u>	<u>Mississauga, Ontario, Canada</u>	<u>85,200,000</u>	<u>Common</u>	<u>21.56%</u>	_____
_____	_____	_____	_____	_____	_____	_____

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: JDT Legal, PLLC
Address 1: 897 W Baxter Dr.
Address 2: South Jordan, UT 84095
Phone: 801-810-4465
Email: jeff@jdt-legal.com

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Melson Liao
Title: President / CEO
Relationship to Issuer: President / CEO

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Caren Currier
Title: Consultant
Relationship to Issuer: Consultant

Describe the qualifications of the person or persons who prepared the financial statements:⁵ 25 years of accounting history.

Provide the following qualifying financial statements:

- Audit letter, if audited;

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Melson Liao certify that:

1. I have reviewed this Disclosure Statement for GLOBAL PHARMATECH INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 1., 2024 [Date]

/s/Melson Liao [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Melson Liao, certify that:

1. I have reviewed this Disclosure Statement for GLOBAL PHARMATECH INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 1, 2024 [Date]

/s/Melson Liao [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

to realize any future tax benefits from its unused net operating losses, no deferred tax asset relating to those losses has been recorded.

Changsha Botaniex, Inc. the subsidiary of GBLP, has been operating in China, has no tax income tax payable.

NOTE 4: COMMITMENTS

Changsha Botaniex, Inc. owns a 4,000 square feet office, located at 1-403, Building A4, Lu-Valley Compark, 27 Wenxuan Road, Lu-Valley High-Tech Development District, Changsha, China 410205

NOTE 5: NOTE PAYABLE

The company has Five convertible notes to Related Parties. \$40,000.00 dated July 1, 2021 to Kingstone Financial Inc, which was assigned to Haizhen Liao on October 18, 2022 and \$10,000 dated August 1, 2021 to Kingstone Financial Inc. which was assigned to Xiyu Zhang on October 18, 2022, and \$10,000 dated March 24, 2022 and dated November 15, 2022 to Juan Peng, and \$0,000 dated on July 21, 2023 to Haizhen Liao. The FIVE Notes are payable on demand and can be converted up to 9.99% at a time at a conversion rate of 1 \$.001..

There is no interest accrued on these Notes.

In June, 2023, GBLP's subsidray, Vitalia Health Inc. got a loan of CAD10,000 with 10% annual interst from Ruiqi Sheng.

NOTE 6: CONSOLIDATION INFORMATION

The financials provided are consolidated financials with the subsidiaries.

NOTE 7: SHAREHOLDER NOTES PAYABLE

These notes are listed above as they are also related parties.

NOTE 8: LITIGATION

None

GLOBAL PHARMATECH INC.
Balance Sheet Prev Year Comparison
As of June 30, 2024

	<u>Jun 30, 24</u>	<u>Jun 30, 23</u>
ASSETS		
Current Assets		
Checking/Savings	29,010.90	21,988.33
Other Current Assets		
Accounts Receivable	194,533.45	131,829.74
Advance to Suppliers	6,831.96	4,056.30
Inventory	19,055.17	19,045.67
Other Current Assets	1,037.89	3,228.10
Total Other Current Assets	<u>221,458.47</u>	<u>158,159.81</u>
Total Current Assets	250,469.37	180,148.14
Fixed Assets	94,698.26	112,964.07
Other Assets		
Goodwill	82,897.26	82,897.26
Intangible Assets	17,817.92	17,596.06
Total Other Assets	<u>100,715.18</u>	<u>100,493.32</u>
TOTAL ASSETS	<u><u>445,882.81</u></u>	<u><u>393,605.53</u></u>
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities		
Other Current Liabilities		
Accts Payable Botaniex	306,225.20	227,072.23
advances from customers	167,783.69	163,434.37
Due to Caren Currier	5,940.00	2,102.70
Loan - Melson	411.84	200.00
Loan - Ruiqui Sheng	30,000.00	10,000.00
Notes Payable - Kingstone	50,000.00	50,000.00
Other Current Liabilites	0.00	8,669.64
Other Payables & Accruals	130,855.35	168,426.48
Total Other Current Liabilities	<u>691,216.08</u>	<u>629,905.42</u>
Total Current Liabilities	<u>691,216.08</u>	<u>629,905.42</u>
Total Liabilities	691,216.08	629,905.42
Equity		
Additional Paid in Capital	11,729,893.05	11,732,365.00
Common Stock	45,371.00	45,371.00
Common Stock - Botaniex	112,360.00	5,000.00
Preferred Stock	9,750.00	9,750.00
FOREX	21,036.36	15,655.47
Accumulated Deficit	-12,163,743.68	-12,039,441.36
Total Equity	<u>-245,333.27</u>	<u>-236,299.89</u>
TOTAL LIABILITIES & EQUITY	<u><u>445,882.81</u></u>	<u><u>393,605.53</u></u>

1:21 PM

08/03/24

Accrual Basis

GLOBAL PHARMATECH INC.
Profit & Loss Prev Year Comparison
April through June 2024

	<u>Apr - Jun 24</u>	<u>Apr - Jun 23</u>
Ordinary Income/Expense		
Income	113,456.57	7,375.00
Cost of Goods Sold	108,251.05	2,557.42
Gross Profit	5,205.52	4,817.58
Expense		
Bank Service Charges	20.11	90.33
Business and Sales Tax	0.00	2,413.71
Interest Expense	0.00	0.16
Legal Fees	1,000.00	0.00
Office Supplies	6,025.50	14,453.20
OTC Fees	5,940.00	5,760.00
Professional Fees	250.00	250.00
Selling Expenses	25,362.44	12,873.10
Total Expense	38,598.05	35,840.50
Net Ordinary Income	-33,392.53	-31,022.92
Other Income/Expense		
Other Income	630.87	357.29
Net Other Income	630.87	357.29
Net Income	<u><u>-32,761.66</u></u>	<u><u>-30,665.63</u></u>

GLOBAL PHARMATECH INC.
Statement of Cash Flows
April through June 2024

	<u>Apr - Jun 24</u>	<u>Apr - Jun 23</u>
OPERATING ACTIVITIES		
Net Income	-32,761.66	-30,665.63
Adjustments to reconcile Net Income to net cash provided by operations:		
Accounts Receivable	-56,482.57	6,793.21
Advance to Suppliers	30.62	209.02
Inventory	4,613.82	369.64
Other Current Assets	1,820.05	-2,789.14
Related Party Receivable	0.00	0.00
Accounts Payable	0.00	0.00
Accts Payable Botaniex	85,692.23	-11,662.94
advances from customers	1,336.33	-8,421.80
Current Portion-Long Term Debt	0.00	0.00
Due to Caren Currier	5,940.00	1,186.00
Loan - Melson	0.00	200.00
Loan - Ruiqui Sheng	0.00	10,000.00
Notes Payable - Kingstone	0.00	0.00
Other Current Liabilites	0.00	8,669.64
Other Payables & Accruals	14,315.58	-2,233.86
Payroll Liabilities	-13,358.54	0.00
Tax Payable	0.00	0.00
Net cash provided by Operating Activities	<u>11,145.86</u>	<u>-28,345.86</u>
INVESTING ACTIVITIES		
Accumulated Depreciation	5,405.42	10,963.90
Fixed Assets	0.00	0.00
Furniture and Equipment	0.00	0.00
Goodwill	0.00	-359.18
Intangible Assets	0.00	942.02
Land, Lease	0.00	0.00
Property, Plant & Equip	0.00	0.00
Net cash provided by Investing Activities	<u>5,405.42</u>	<u>11,546.74</u>
FINANCING ACTIVITIES		
Additional Paid in Capital	7,528.05	0.00
Capital Stock	0.00	0.00
Common Stock	0.00	0.00
Common Stock - Botaniex	0.00	0.00
Dividends Paid	0.00	0.00
FOREX	-10,479.14	18,146.27
Minority Interest	0.00	0.00
Opening Balance Equity	0.00	0.00
Preferred Stock	0.00	0.00
Retained Earnings	0.00	0.00
Retained Earnings - Botaniex	0.00	0.00
Subscription Receivable	0.00	0.00
Net cash provided by Financing Activities	<u>-2,951.09</u>	<u>18,146.27</u>

GLOBAL PHARMATECH INC.
Statement of Cash Flows
April through June 2024

	<u>Apr - Jun 24</u>	<u>Apr - Jun 23</u>
Net cash increase for period	13,600.19	1,347.15
Cash at beginning of period	15,410.71	20,641.18
Cash at end of period	<u><u>29,010.90</u></u>	<u><u>21,988.33</u></u>

Global Pharmatech, Inc.
Shareholders' Equity (Deficiency)
(Unaudited)

	Common Stock		Common Stock-Botaniex		Preferred Stock A		Add'l Paid in Capital	Accumulated Deficit	Total Stockholders' Equity/(Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance December 31, 2022	282,851,785	34,135	5,000,000	5,000	9,750,000	9,750	11,732,365	(12,005,236)	(207,952)
Correct Value in Accounting Documents-Botaniex									-
Shares Issued	112,360,000	11,236						-2491	(2,491)
Net Gain/(loss) for period ended March 31, 2023								(31,074)	(31,074)
Balance March 31, 2023	395,211,785	45,371	5,000,000	5,000	9,750,000	9,750	11,732,365	(12,038,801)	(241,517)
FOREX								18,147	18,147
Shares Issued									-
Net Gain/(loss) for period ended June 30, 2023								(30,666)	(30,666)
Balance June 30, 2023	395,211,785	45,371	5,000,000	5,000	9,750,000	9,750	11,732,365	(12,051,320)	(254,036)
Correct Value in Accounting Documents-Botaniex									17,736
FOREX								(9,665)	(9,665)
Shares Issued			107,360,000	107,360					107,360
Net Gain/(loss) for period ended September 30, 2023							10,000	(44,479)	(34,479)
Balance September 30, 2023	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,742,365	(12,105,464)	(173,084)
FOREX								-	-
Shares Issued									-
Net Gain/(loss) for period ended December 31, 2023							(20,000)	(32,282)	(52,282)
Balance December 31, 2023	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,722,365	(12,137,746)	(225,366)
FOREX								16,544	16,544
Shares Issued									-
Net Gain/(loss) for period ended March 31, 2024								(9,780)	(9,780)
Adj for consolidated									8981
Balance March 31, 2024	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,722,365	(12,130,982)	(209,621)
FOREX									(10,478)
Shares Issued									-
Net Gain/(loss) for period ended June 30, 2024							7,528	(32,762)	(25,234)
Adj for consolidated									
Balance June 30, 2024	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,729,893	(12,163,744)	(245,333)

GLOBAL PHARMATECH INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For The Period Ended Jun3 30, 2024

NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies followed in the preparation of these financial statements:

Organizational Information: GLOBAL PHARMATECH INC. (the Company) was incorporated in 2001 in the State of Delaware.

Industry Information: Global Pharmatech, Inc. through its subsidiary, Botaniex, Inc, which is a market-oriented supplier & manufacturer of natural ingredients (botanical extracts/herbal extracts and herbal formulations) for the Industries of Dietary Supplements, Functional Foods, Functional Beverages, Cosmetics and Pharmaceuticals. By co-operating with the strategic partners like universities, Botaniex's R&D team is dedicated to development of the new natural ingredients and the herbal formulations focusing on men's health and women's health. In addition, both the advanced equipment and sophisticated technology are employed to produce the high quality and customized botanical extracts and herbal formula. We also provide customers with value added services such as Private Labels, Contract Manufacturing, and etc. Global Pharmatech's operations are currently based in Changsha, China.

Global Pharmatech, Inc.(GBLP) incorporated a wholly owned subsidiary - Vitalia Health Inc. based in Toronto, Canada on April 29, 2023. The subsidiary will focus on manufacturing and marketing of dietary supplements focus on anti-aging, anti-diabetics, immune enhancement, energy booster, and weight management as well as distribution of botanical extracts/herbal extracts in Canada.

Basis of Presentation: The accounting records of the Company are maintained on the accrual basis and the accompanying financial statements are presented on the accrual basis.

Depreciation and Amortization: The cost of property and equipment is depreciated over the estimated useful lives of the related assets using the accelerated recovery periods of the Internal Revenue Service. Purchased software is amortized on the straight-line basis over five years; organization expense and trademarks are amortized on the straight-line method over sixty months.

Accounts Receivable: The accounts receivable arises in the normal course of business of providing services to Customers. Accounts are written-off as they are deemed uncollectible based upon a periodic review of the accounts. At this time the company has no receivables.

Concentration of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of bank deposits and trade accounts receivable. The Company has concentrated its credit risk for cash by maintaining deposits in financial institutions within the geographic region of Lincoln, Nebraska, which may at times

exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC). There is no excess deposit liabilities at this time. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk to cash. Concentrations of credit risk with respect to accounts receivable arise because the Company grants unsecured credit in the form of trade accounts receivable to its customers.

Management Estimations: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the period. Actual results could differ from those estimates. GLOBAL PHARMATECH INC.

Cash and Equivalents: For purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and certificates of deposit with original maturities of 90 days or less to be cash or cash equivalents.

Revenue Recognition: Revenues on subscription contracts are recognized monthly over the life of the contract. Amounts that have been invoiced are recorded in accounts receivable and revenue or deferred revenue, depending upon whether the revenue recognition criteria have been met.

Inventory: The Company maintains its inventory on a perpetual basis utilizing the first-in first-out (FIFO) method. There is no inventory at this time.

NOTE 2: GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has minimal working capital and net losses from inception. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required, and ultimately to attain profitability. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3: INCOME TAX

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes. SFAS 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. SFAS 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Consequently, because of uncertainty about the Company's ability